Madrigal Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Madrigal Pharmaceuticals will announce Q4 and full-year 2025 results on Feb. 19, followed by a webcast for details.

Quiver AI Summary

Madrigal Pharmaceuticals, Inc. announced that it will release its fourth-quarter and full-year 2025 financial results on February 19, 2026, before the U.S. markets open. Following the release, a live webcast will be held at 8 a.m. Eastern Time to discuss the financial and operational results, accessible via the company's Investor Relations website, with registration recommended 15 minutes in advance. Madrigal is a biopharmaceutical company focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), with its medication Rezdiffra being the first approved treatment for MASH with moderate to advanced fibrosis. An ongoing Phase 3 trial is also assessing Rezdiffra for compensated MASH cirrhosis.

Potential Positives

Madrigal Pharmaceuticals will release its fourth-quarter and full-year 2025 financial results on Feb. 19, 2026, highlighting transparency and communication with stakeholders.
The live webcast following the results announcement allows for direct engagement between management and investors, demonstrating the company's commitment to investor relations.
Madrigal is the first and only company to have a medication approved for the treatment of MASH with moderate to advanced fibrosis, positioning it as a leader in addressing a high unmet medical need.
An ongoing Phase 3 outcomes trial for Rezdiffra specifically targeting compensated MASH cirrhosis indicates continued progress and investment in developing treatments for this serious condition.

Potential Negatives

Significant anticipation for the financial results could indicate previous poor performance, raising concerns among investors about the company's financial health.
The focus on an ongoing Phase 3 trial may suggest reliance on a single product (Rezdiffra), which could be risky if the trial does not meet expectations.
The niche focus on MASH could limit the company's market potential and attractiveness to a broader investor base.

FAQ

When will Madrigal Pharmaceuticals release its financial results?

Madrigal Pharmaceuticals will release its fourth-quarter and full-year 2025 financial results on February 19, 2026.

What time is the live webcast for Madrigal's financial results?

The live webcast will be hosted at 8 a.m. Eastern Time on February 19, 2026.

How can I access the webcast for Madrigal's financial results?

The webcast can be accessed in the Investor Relations section of Madrigal Pharmaceuticals' website.

What is Rezdiffra, developed by Madrigal Pharmaceuticals?

Rezdiffra is a once-daily, oral medication for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Is Rezdiffra approved for any specific conditions?

Yes, Rezdiffra is approved by the FDA and European Commission for treating MASH with moderate to advanced fibrosis.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$MDGL Insider Trading Activity

$MDGL insiders have traded $MDGL stock on the open market 248 times in the past 6 months. Of those trades, 54 have been purchases and 194 have been sales.

Here’s a breakdown of recent trading of $MDGL stock by insiders over the last 6 months:

PAUL A FRIEDMAN has made 0 purchases and 67 sales selling 225,580 shares for an estimated $91,113,997.
BROS. ADVISORS LP BAKER has made 54 purchases buying 165,683 shares for an estimated $61,921,024 and 0 sales.
REBECCA TAUB has made 0 purchases and 53 sales selling 86,648 shares for an estimated $37,972,935.
KENNETH BATE has made 0 purchases and 17 sales selling 26,575 shares for an estimated $11,679,362.
WILLIAM JOHN SIBOLD (President and CEO) has made 0 purchases and 5 sales selling 18,872 shares for an estimated $8,448,859.
RICHARD S LEVY has made 0 purchases and 14 sales selling 8,500 shares for an estimated $4,428,197.
MARDI DIER (EVP and CFO) has made 0 purchases and 15 sales selling 4,173 shares for an estimated $2,413,416.
CAROLE HUNTSMAN (Chief Commercial Officer) has made 0 purchases and 13 sales selling 2,868 shares for an estimated $1,532,325.
SHANNON T KELLEY (General Counsel) has made 0 purchases and 10 sales selling 1,996 shares for an estimated $823,799.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$MDGL Hedge Fund Activity

We have seen 189 institutional investors add shares of $MDGL stock to their portfolio, and 157 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP added 397,076 shares (+5381.2%) to their portfolio in Q3 2025, for an estimated $182,122,878
JANUS HENDERSON GROUP PLC removed 349,063 shares (-15.9%) from their portfolio in Q3 2025, for an estimated $160,101,235
ADAGE CAPITAL PARTNERS GP, L.L.C. removed 287,663 shares (-76.5%) from their portfolio in Q3 2025, for an estimated $131,939,511
GOLDMAN SACHS GROUP INC added 196,260 shares (+103.4%) to their portfolio in Q3 2025, for an estimated $90,016,611
PAULSON & CO. INC. removed 182,000 shares (-8.7%) from their portfolio in Q3 2025, for an estimated $83,476,120
BAKER BROS. ADVISORS LP added 165,683 shares (+8.4%) to their portfolio in Q3 2025, for an estimated $75,992,164
CITADEL ADVISORS LLC removed 158,967 shares (-76.7%) from their portfolio in Q3 2025, for an estimated $72,911,804

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$MDGL Analyst Ratings

Wall Street analysts have issued reports on $MDGL in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citizens issued a "Market Outperform" rating on 01/20/2026
HC Wainwright & Co. issued a "Buy" rating on 11/21/2025
Oppenheimer issued a "Outperform" rating on 11/20/2025
Truist Securities issued a "Buy" rating on 11/19/2025
Canaccord Genuity issued a "Buy" rating on 11/13/2025
Cantor Fitzgerald issued a "Overweight" rating on 11/05/2025
Piper Sandler issued a "Overweight" rating on 10/15/2025

To track analyst ratings and price targets for $MDGL, check out Quiver Quantitative's $MDGL forecast page.

$MDGL Price Targets

Multiple analysts have issued price targets for $MDGL recently. We have seen 13 analysts offer price targets for $MDGL in the last 6 months, with a median target of $620.0.

Here are some recent targets:

Eliana Merle from Barclays set a target price of $964.0 on 01/28/2026
Jonathan Wolleben from Citizens set a target price of $745.0 on 01/20/2026
Yasmeen Rahimi from Piper Sandler set a target price of $900.0 on 12/19/2025
William Woods from B. Riley Securities set a target price of $670.0 on 12/11/2025
Andrew S. Fein from HC Wainwright & Co. set a target price of $620.0 on 11/21/2025
Jay Olson from Oppenheimer set a target price of $650.0 on 11/20/2025
Srikripa Devarakonda from Truist Securities set a target price of $640.0 on 11/19/2025

Full Release

CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 19, 2026, prior to the open of the U.S. financial markets.

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website . To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

The webcast will be available approximately two hours after the live webcast.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com .

Investor Contact
Tina Ventura, Madrigal Pharmaceuticals, Inc., [email protected]

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., [email protected]